Wednesday, February 10, 2010, 8:30pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Abraxis BioScience, Inc. (ABII)

At 5:00AM SGT: 35.22 USD   0.00 (0.00%)  
 MORE ON ABII 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Abraxis Bioscience Inc. (NasdaqNM:ABII) Delayed quote dataEdit
Last Trade:35.22 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:35.22
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:N/A
Day's Range:N/A - N/A
52wk Range:24.52 - 73.98
Volume:0
Avg Vol (3m):47,263.5
Market Cap:1.41B
P/E (ttm):N/A
EPS (ttm):-6.63
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Use Y! Toolbar to track stocks
 Add ABII to Portfolio   Download Data

 HEADLINES 
•Abraxis Bioscience to Spin Off Abraxis Health in 2010
at Seeking Alpha (Sun, Jan 31)
•Abraxis BioScience downgraded by Merriman
Briefing.com (Fri, Jan 29)
•ABRAXIS BIOSCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Thu, Jan 28)
•Abraxis BioScience Confirms Plan to Spin-off Abraxis Health in 2010 and Announces Management Structure
Business Wire (Thu, Jan 28)
•$10,000 Will Be 2010 Consumable Cost For Human Genome Sequencing: Competition Developing Rapidly In This Sector According To First Analysis Equity Valuation Expert
Wall Street Transcript (Wed, Jan 27)
•Abraxis BioScience to Present at 28th Annual J.P. Morgan Healthcare Conference
Business Wire (Fri, Jan 8)
•ABRAXIS BIOSCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Wed, Dec 16)
•[video] Craig Barrett's Healthy Endeavor
at Forbes.com (Thu, Dec 10)
•Abraxis Provides Overview of ABRAXANE® Study Results to Be Presented at the 32nd Annual San Antonio Breast Cancer Symposium
Business Wire (Tue, Dec 8)
•[$$] Small-Cap Weakness Shrinks a Nanotech ETF
at RealMoney by TheStreet.com (Sat, Nov 28)
•Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
Wall Street Transcript (Fri, Nov 20)
More Headlines for ABII...
 ANALYST 
EPS Est (next year) (Dec-09) :-3.10
EPS Est (in 2 years) (Dec-10) :-2.13
Avg Rec (current)*:2.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Abraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices